Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …

Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …

Currently, the world is facing the pandemic of a novel strain of beta‐coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Acute respiratory distress …

A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …

Background The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms
to severe complications, including acute respiratory distress syndrome. In this syndrome …

COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2),
emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease …

Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …

The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin
6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory …

Abstract The coronavirus disease 2019 (COVID-19) virus has spread all over the world.
Scientists are trying to discover drugs as effective treatment for patients with COVID-19. So …

Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …